Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Patiromer

(Veltassa®)

Veltassa®

Drug updated on 3/28/2024

Dosage FormSuspension (oral; 8.4 g, 16.8 g, 25.2 g)
Drug ClassPotassium binders
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • For the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Patiromer (Veltassa) is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.
  • A total of 13 systematic reviews/meta-analyses were reviewed to gather information about patiromer's safety and effectiveness.
  • In heart failure patients at high risk of developing hyperkalemia, patiromer has been shown to increase the use of renin-angiotensin-aldosterone inhibitors, reducing incidence rates but increasing prevalence rates for hypokalemia.
  • For chronic kidney disease (CKD) patients with both hyperkalemia and hyperphosphatemia, patiromer effectively reduces serum phosphorus levels within two weeks while maintaining this reduction over four weeks.
  • Compared to other potassium binders like sodium polystyrene sulfonate (SPS) or calcium polystyrene sulfonate (CPS), patiromer may reduce all-cause mortality in CKD patients with fewer gastrointestinal adverse effects reported than those associated with SPS or CPS usage.
  • Despite its efficacy, a significant concern regarding the use of Patirometer is an increased risk for hypokalemia which necessitates careful monitoring during treatment periods due to potential electrolyte imbalances that could occur as a result from its administration.
  • Gastrointestinal tolerability was noted as one area where Patirormeter outperformed other tested potassium binders such as SPS or CPS; constipation and diarrhea were among most frequently reported side-effects however their occurrence rate was either on par or somewhat better compared against these alternatives.
  • Patirometer demonstrated effectiveness across various stages Chronic Kidney Disease including those who are undergoing RAAS inhibitor therapy; it’s well-tolerated nature coupled manageable GI-related side effect profile makes it suitable long-term management option within this patient population.

Product Monograph / Prescribing Information

Document TitleYearSource
Veltassa (patiromer) Prescribing Information.2021FDA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials.2023Clinical Research in Cardiology
Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials2023American journal of kidney diseases
The Efficacy and Safety of Patiromer for Heart Failure Patients: A Systematic Review and Meta-Analysis2023Cardiovascular drugs and therapy
Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis2023European journal of internal medicine
Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia2022European journal of pharmacology
Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials2022Kidney360
Clinical and Pharmacoeconomic combined report patiromer (Veltassa).2021CADTH
Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis.2021Current Therapeutic Research, Clinical and Experimental
Binding potassium to improve treatment with renin-angiotensin-aldosterone system inhibitors: results from multiple one-stage pairwise and network meta-analyses of clinical trials.2021Frontiers in Medicine
Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis2021Journal of clinical medicine
Patiromer for treating hyperkalaemia.2020NICE
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. 2020Cochrane Database of Systematic Reviews
Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials2020Progress in cardiovascular diseases
Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review.2019Pharmacy Practice
Evidence in support of hyperkalaemia management strategies: A systematic literature review.2018The International Journal of Clinical Practice

Clinical Practice Guidelines

Document TitleYearSource
Clinical Practice Guidelines: treatment of acute hyperkalaemia in adults.2020The Renal Association